Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein

Virology

Volumn 239, Issue 1, 1997, Pages 108-118

  Milich, Lynn ^b   Margolin, Barry H ^a   Swanstrom, Ronald ^b  

^a IL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN TARGETING; SYNCYTIUM;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031455910     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8821     Document Type: Article

References (62)

1. Asjo B., Morfeldt-Manson L., Albert J., Biberfeld G., Karlsson A., Lidman K., Fenyo E. M. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. 2:1986;660-662.
2. Back N. K., Smit L., DeJong J. J., Keulen W., Schutten M., Goudsmit J., Tersmette M. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology. 199:1994;431-438.
3. Bickel P. J., Cosman P. C., Olshen R. A., Spector P. C., Rodrigo A. G., Mullins J. I. Covariability of V3 loop amino acids. AIDS Res. Hum. Retroviruses. 12:1996;1401-1411.
4. Bou-Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P., Norcross M. A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:1994;6006-6013.
5. Boyd M. T., Simpson G. R., Cann A. J., Johnson M. A., Weiss R. A. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J. Virol. 67:1993;3649-3652.
6. Carrillo A., Ratner L. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: Role of the V3 loop and C4 envelope determinants. J. Virol. 70:1996;1301-1309.
7. Carrillo A., Trowbridge D. B., Westervelt P., Ratner L. Identification of HIV-1 determinants for T Lymphoid cell line infection. Virology. 197:1993;817-824.
8. Cheng-Mayer C., Homsy J., Evans L. A., Levy J. A. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc. Natl. Acad. Sci. USA. 85:1988a;2815-2819.
9. Cheng-Mayer C., Seto D., Tateno M., Levy J. A. Biologic features of HIV-1 that correlate with virulence in the host. Science. 240:1988b;80-82.
10. Chesebro B., Wehrly K., Nishio J., Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism. J. Virol. 66:1992;6547-6554.
11. Chesebro B., Wehrly K., Nishio J., Perryman S. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J. Virol. 70:1996;9055-9059.
12. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
13. Chowdhury I. H., Potash M. J., Volsky D. J. Redefinition of tropism of common macrophage-tropic human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 11:1995;1467-1471.
14. Conley A. J., Kessler J. A. II, Boots L. J., McKenna P. M., Schleif W. A., Emini E. A., Mark G. E. III, Katinger H., Cobb E. K., Lunceford S. M., Rouse S. R., Murthy K. K. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:1996;6751-6758.
15. Cornelissen M., Hogervorst E., Zorgdrager F., Hartman S., Goudsmit J. Maintenance of syncytium-inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp120 V2 domain without fixed positions, elongation, or relocated N-linked glycosylation sites. AIDS Res. Hum. Retroviruses. 11:1995;1169-1175.
16. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., DiMarzio P., Marmon S., Sutton R. E., Hill C. M., Davis C. B., Peiper S. C., Schall T. J., Littman D. R., Landau N. R. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
17. Distler O., McQueen P. W., Tsang M. L., Evans L. A., Hurren L., Byrne C., Penny R., Cooper D. A., Delaney S. F. Primary structure of the V3 region of gp120 from sequential human immunodeficiency virus type 1 isolates obtained from patients from the time of seroconversion. J. Infect. Dis. 172:1995;1384-1387.
18. Ebenbichler C., Westervelt P., Carrillo A., Henkel T., Johnson D., Ratner L. Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: Evidence for two distinct conformations. AIDS. 7:1993;639-646.
19. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M., Eichberg J. W., Murthy K. K. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 355:1992;728-730.
20. Estaquier J., Gras-Masse H., Boutillon C., Ameisen J. C., Capron A., Tartar A., Auriault C. The mixotope: A combinatorial peptide library as a T cell and B cell immunogen. Eur. J. Microbiol. 24:1994;2789-2795.
21. Fauci A. S. Host factors and the pathogenesis of HIV-induced disease. Nature. 384:1996;529-534.
22. Fouchier R. A., Broersen S. M., Brouwer M., Tersmette M., Van't Wout A. B., Groenink M., Schuitemaker H. Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype. AIDS Res. Hum. Retroviruses. 11:1995a;1473-1478.
23. Fouchier R. A., Brouwer M., Broersen S. M., Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J. Clin. Microbiol. 33:1995b;906-911.
24. Ghiara J. B., Stura E. A., Stanfield R. L., Profy A. T., Wilson I. A. Crystal structure of the principal neutralization site of HIV-1. Science. 264:1994;82-85.
25. MN. J. Infect. Dis. 173:1996;330-339.
26. Groenink M., Fouchier R. A., Broersen S., Baker C. H., Koot M., Van't Wout A. B., Huisman H. G., Miedema F., Tersmette M., Schuitemaker H. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science. 260:1993;1513-1516.
27. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D., Mathews T. J. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA. 86:1989;6768-6772.
28. Koot M., Keet I. P., Vos A. H., de Goede R. E., Roos M. T., Coutinho R. A., Miedema F., Schellekens P. T., Tersmette M. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Int. Med. 118:1993;681-688.
29. Korber B. T., Farber R. M., Wolpert D. H., Lapedes A. S. Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: An information theoretic analysis. Proc. Natl. Acad. Sci. USA. 90:1993;7176-7180.
30. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P., Holley L. H., Karplus M., Bolognesi D. P., Mathews T. J., Emini E. A., Putney S. D. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science. 249:1990;932-935.
31. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P., Holley L. H., Karplus M., Bolognesi D. P., Mathews T. J., Emini E. A., Putney S. D. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: Corrections and clarifications. Science. 251:1991a;811.
32. LaRosa G. J., Weinhold K., Profy A. T., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P., Bolognesi D. P., Matthews T. J., Emini E. A., Putney S. D. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: Further clarifications. Science. 253:1991b;1146.
33. Leonard C. K., Spellman M. W., Riddle L., Harris R. J., Thomas J. N., Gregory T. J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:1990;10373-10382.
34. McNearney T., Hornickova Z., Markham R., Birdwell A., Arens M., Saah A., Ratner L. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc. Natl. Acad. Sci. USA. 89:1992;10247-10251.
35. Mehta C. R., Patel N. R. A network algorithm for performing Fisher's Exact Test inrxc. J. Am. Stat. Assoc. 78:1983;427-434.
36. Miedema F., Meyaard L., Koot M., Klein M. R., Roos M. T., Groenink M., Fouchier R. A., Van't Wout A. B., Tersmette M., Schellekens P. T., Schuitemaker H. Changing virus-host interactions in the course of HIV-1 infection. Immunol. Rev. 140:1994;35-72.
37. Milich L., Margolin B., Swanstrom R. V3 loop of the human immunodeficiency virus type 1 Env protein: Interpreting sequence variability. J. Virol. 67:1993;5623-5634.
38. Moore J. P., Thali M., Jameson B. A., Vignaux F., Lewis G. K., Poon S. W., Charles M., Fung M. S., Sun B., Durda P. J., Akerblom L., Wahren B., Ho D. D., Sattentau Q. J., Sodroski J. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: Probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J. Virol. 67:1993;4785-4796.
39. Myers G., Korber B., Foley B., Jeang K.-T., Mellons J. W., Wain-Hobson S. Human Retroviruses and AIDS 1996. 1996;Los Alamos National Laboratory, Los Alamos.
40. Palmer C., Balfe P., Fox D., May J. C., Frederiksson R., Fenyo E. M., McKeating J. A. Functional characterization of the V1V2 region of human immunodeficiency virus type 1. Virology. 220:1996;436-449.
41. Profy A. T., Salinas P. A., Eckler L. I., Dunlop N. M., Nara P. L., Putney S. D. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J. Immunol. 144:1990;4641-4647.
42. Resnick D. A., Smith A. D., Gesiler S. C., Zhang A., Arnold E., Arnold G. F. Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1. J. Virol. 69:1995;2406-2411.
43. Rini J. M., Stanfield R. L., Stura E. A., Salinas P. A., Profy A. T., Wilson I. A. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc. Natl. Acad. Sci. USA. 90:1993;6325-6329.
44. Rubinstein A., Goldstein H., Pettoello-Mantovani M., Mizrachi Y., Bloom B. R., Furer E., Althaus B., Que J. U., Hasler T., Cryz S. J. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS. 9:1995;243-251.
45. Schellekens P. T., Tersmette M., Roos M. T., Keet R. P., deWolf F., Coutinho R. A., Miedema F. Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS. 6:1992;665-669.
46. Schonning K., Jansson B., Olofsson S., Nielsen J. O., Hansen J. S. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology. 218:1996;134-140.
47. Schuitemaker H., Koot M., Kootstra N. A., Dercksen M. W., deGoede R. E., vanSteenwijk R. P., Lange J. M., Schattenkerk J. K., Miedema F., Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66:1992;1354-1360.
48. Schuitemaker H., Kootstra N. A., deGoede R. E., deWolf F., Miedema F., Tersmette M. Monocytotropic human immunodeficiency virus 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 65:1991;356-363.
49. Seillier-Moiseiwitsch F., Margolin B. H., Swanstrom R. Genetic variability of the human immunodeficiency virus: Statistical and biological issues. Annu. Rev. Genet. 28:1994;559-596.
50. Simmons G., Wilkinson D., Reeves J. D., Dittmar M. T., Beddows S., Weber J., Carnegie G., Desselberger U., Gray P. W., Weiss R. A., Clapham P. R. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70:1996;8355-8360.
51. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:1995;4413-4422.
52. Tersmette M., Gruters R. A., de Wolf F., de Goede R. E., Lange J. M., Schellekens P. T., Goudsmit J., Huisman H. G., Miedema F. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J. Virol. 63:1989a;2118-2125.
53. Tersmette M., Lange J. M., de Goede R. E., de Wolf F., Eeftink-Schattenkerk J. K., Schellekens P. T., Coutinho R. A., Huisman J. G., Goudsmit J., Miedema F. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and mortality. Lancet. 1:1989b;983-985.
54. Trkola A., Dragic T., Arthos J., Binley J. M., Olson W. C., Allaway G. P., Cheng-Mayer C., Robinson J., Maddon P. J., Moore J. P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 384:1996;184-187.
55. Van't Wout A. B., Kootstra N. A., Mulder-Kampinga G. A., Albrecht-van Lent N., Scherpbier H. J., Veenstra J., Boer K., Coutinho R. A., Miedema F., Schuitemaker H. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J. Clin. Invest. 94:1994;2060-2067.
56. Vancott T. C., Polonis V. R., Loomis L. D., Michael N. L., Nara P. L., Birx D. L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses. 11:1995;1379-1391.
57. MN. J. Immunol. 153:1994;1895-1904.
58. Willey R. L., Theodore T. S., Martin M. A. Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope. J. Virol. 68:1994;4409-4419.
59. Wu L., Gerard N. P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A. A., Desjardin E., Newman W., Gerard C., Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:1996;179-183.
60. Wyatt R., Thali M., Tilley S., Pinter A., Posner M., Ho D., Robinson J., Sodroski J. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J. Virol. 66:1992;6997-7004.
61. Yoshimura K., Matsushita S., Hayashi A., Takatsuki K. Relationship of HIV-1 envelope V2 and V3 sequences of the primary isolates to the viral phenotype. Microbiol. Immunol. 40:1996;277-287.
62. Zhu T., Mo H., Wang N., Nam D. S., Cao Y., Koup R. A., Ho D. D. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 261:1993;1179-1181.